trending Market Intelligence /marketintelligence/en/news-insights/trending/6EhX_Z685tfMUwZQBOkssQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biofrontera acquires dermatology company Cutanea for $1

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biofrontera acquires dermatology company Cutanea for $1

Biofrontera AG will acquire U.S.-based dermatology company Cutanea Life Sciences Inc., which markets an acne treatment and other products, for $1.

Germany's Biofrontera will acquire the company through a subsidiary from Japan's Maruho Co. Ltd., which holds a 20% stake in Biofrontera, according to a March 25 press release.

Besides the acne treatment Aktipak, Cutanea in November 2018 launched Xepi, a treatment for a bacterial skin infection called impetigo.

Maruho plans to provide up to $7.3 million in startup funds for the development of Biofrontera's drug candidates through the transaction. Profits from Aktipak and Xepi will later be split between Maruho and Biofrontera.